{"id":{"repo_id":"birmingham","oai_identifier":"oai:etheses.bham.ac.uk:5420"},"canonical_url":"https://search.ndltd.org/etd/birmingham/oai:etheses.bham.ac.uk:5420","repository":{"repo_id":"birmingham","name":"University of Birmingham","base_url":"https://etheses.bham.ac.uk/cgi/oai2"},"display":{"title":"An investigation into mechanisms of action of colchicine, zinc acetate and paracetemol - potential candidates for drug repurposing in head and neck cancer therapy","abstract":"The incidence of head and neck cancers (HNC) is on the rise. The common therapies used, are associated with long-term toxicities that hamper the quality of life of HNC patients. Novel therapeutic strategies are required to reduce these. As drug discovery is expensive, time consuming and unreliable, in this project we have considered drug repurposing. Paracetemol, zinc acetate and colchicine are used for pain relief, common cold lozenges and gout treatment, respectively. We initially assessed their efficacy on the proliferation of a HNC cell line, SCC040, using an Alamar blue colometric assay. Results indicate zinc acetate significantly inhibited proliferation (62.68 ± 3.75% reduction, p≤0.001) compared to vehicle control. Secondly cell cycle analysis was carried out using propidium iodide staining and flow cytometry analysis. Colchicine was found to be a potent G2/M cell cycle blocker (p≤0.001) compared to its untreated control. Finally the effect of the drugs on the migration of SCC040 cells was assessed using a wound-healing assay. Colchicine was found to significantly inhibit migration compared to its vehicle control (79.55 ± 4.02% reduction p≤0.001). These results suggest that zinc acetate and colchicine are potential candidates for less toxic therapies in HNC patients.","abstract_html":"The incidence of head and neck cancers (HNC) is on the rise. The common therapies used, are associated with long-term toxicities that hamper the quality of life of HNC patients. Novel therapeutic strategies are required to reduce these. As drug discovery is expensive, time consuming and unreliable, in this project we have considered drug repurposing. Paracetemol, zinc acetate and colchicine are used for pain relief, common cold lozenges and gout treatment, respectively. We initially assessed their efficacy on the proliferation of a HNC cell line, SCC040, using an Alamar blue colometric assay. Results indicate zinc acetate significantly inhibited proliferation (62.68 ± 3.75% reduction, p≤0.001) compared to vehicle control. Secondly cell cycle analysis was carried out using propidium iodide staining and flow cytometry analysis. Colchicine was found to be a potent G2/M cell cycle blocker (p≤0.001) compared to its untreated control. Finally the effect of the drugs on the migration of SCC040 cells was assessed using a wound-healing assay. Colchicine was found to significantly inhibit migration compared to its vehicle control (79.55 ± 4.02% reduction p≤0.001). These results suggest that zinc acetate and colchicine are potential candidates for less toxic therapies in HNC patients.","abstract_has_math":false,"creators":["Shakir, Nadia"],"institution":"University of Birmingham","degree_name":"m_rs","degree_level":"m_rs","degree_discipline":null,"degree_department":null,"school":null,"contributors":[],"advisors":[],"committee_chairs":[],"committee_members":[],"year":2014,"date_issued":"2014-12","date_published":"2014-12","updated_at":"2026-11-19T09:28:23Z","subjects":["RC0254 Neoplasms. Tumors. Oncology (including Cancer)"],"languages":["eng"],"rights":[],"rights_urls":[],"identifier_entries":[],"person_identifier_entries":[]},"links":{"outbound_url":null,"outbound_label":null,"outbound_source":null,"record_url":null,"record_label":null,"record_kind":null,"record_source":null,"download_url":"http://etheses.bham.ac.uk//id/eprint/5420/1/Shakir14MRes.pdf","download_label":"Download PDF","download_source":"dc:identifier.uri","access_status":null,"embargo_until":null,"access_note":null},"source_record":{"url":"https://etheses.bham.ac.uk/cgi/oai2?verb=GetRecord&metadataPrefix=uketd_dc&identifier=oai%3Aetheses.bham.ac.uk%3A5420","prefix":"uketd_dc"},"metadata_groups":[{"id":"people","label":"People","entries":[{"key":"dc:contributor.sponsor","label":"Sponsor","values":["na"]},{"key":"dc:creator","label":"Author","values":["Shakir, Nadia"]}]},{"id":"academic_context","label":"Academic Context","entries":[{"key":"dc:date","label":"Dc Date","values":["2014-12"]},{"key":"dc:date.issued","label":"Date","values":["2014-12"]},{"key":"dc:publisher.department","label":"Dc Publisher Department","values":["College of Medical & Dental Sciences","Institute of Cancer Studies"]},{"key":"dc:publisher.institution","label":"Dc Publisher Institution","values":["University of Birmingham"]},{"key":"dc:relation.isreferencedby","label":"Dc Relation Isreferencedby","values":["http://etheses.bham.ac.uk//id/eprint/5420/"]},{"key":"dc:type","label":"Dc Type","values":["Thesis"]},{"key":"dc:type.qualificationlevel","label":"Dc Type Qualificationlevel","values":["m_rs"]},{"key":"dc:type.qualificationname","label":"Dc Type Qualificationname","values":["m_rs"]}]},{"id":"subjects_keywords","label":"Subjects and Keywords","entries":[{"key":"dc:subject","label":"Dc Subject","values":["RC0254 Neoplasms. Tumors. Oncology (including Cancer)"]}]},{"id":"language_rights","label":"Language and Rights","entries":[{"key":"dc:language.dcterms_iso639_2","label":"Language (ISO 639-2)","values":["eng"]}]},{"id":"identifiers","label":"Identifiers","entries":[{"key":"dc:identifier.uri","label":"Identifier URI","values":["http://etheses.bham.ac.uk//id/eprint/5420/1/Shakir14MRes.pdf","http://etheses.bham.ac.uk//id/eprint/5420/2/Decl_IS_Shakir14MRes.pdf"]}]},{"id":"additional","label":"Additional Metadata","entries":[{"key":"dc:description.abstract","label":"Abstract","values":["The incidence of head and neck cancers (HNC) is on the rise. The common therapies used, are associated with long-term toxicities that hamper the quality of life of HNC patients. Novel therapeutic strategies are required to reduce these. As drug discovery is expensive, time consuming and unreliable, in this project we have considered drug repurposing. Paracetemol, zinc acetate and colchicine are used for pain relief, common cold lozenges and gout treatment, respectively. We initially assessed their efficacy on the proliferation of a HNC cell line, SCC040, using an Alamar blue colometric assay. Results indicate zinc acetate significantly inhibited proliferation (62.68 ± 3.75% reduction, p≤0.001) compared to vehicle control. Secondly cell cycle analysis was carried out using propidium iodide staining and flow cytometry analysis. Colchicine was found to be a potent G2/M cell cycle blocker (p≤0.001) compared to its untreated control. Finally the effect of the drugs on the migration of SCC040 cells was assessed using a wound-healing assay. Colchicine was found to significantly inhibit migration compared to its vehicle control (79.55 ± 4.02% reduction p≤0.001). These results suggest that zinc acetate and colchicine are potential candidates for less toxic therapies in HNC patients."]},{"key":"dc:format","label":"Dc Format","values":["application/pdf"]},{"key":"dcterms:accessrights","label":"Dcterms Accessrights","values":["public","staffonly"]},{"key":"dc:title","label":"Title","values":["An investigation into mechanisms of action of colchicine, zinc acetate and paracetemol - potential candidates for drug repurposing in head and neck cancer therapy"]}]}],"canonical_facts":{"dc:contributor.sponsor":["na"],"dc:creator":["Shakir, Nadia"],"dc:date":["2014-12"],"dc:date.issued":["2014-12"],"dc:description.abstract":["The incidence of head and neck cancers (HNC) is on the rise. The common therapies used, are associated with long-term toxicities that hamper the quality of life of HNC patients. Novel therapeutic strategies are required to reduce these. As drug discovery is expensive, time consuming and unreliable, in this project we have considered drug repurposing. Paracetemol, zinc acetate and colchicine are used for pain relief, common cold lozenges and gout treatment, respectively. We initially assessed their efficacy on the proliferation of a HNC cell line, SCC040, using an Alamar blue colometric assay. Results indicate zinc acetate significantly inhibited proliferation (62.68 ± 3.75% reduction, p≤0.001) compared to vehicle control. Secondly cell cycle analysis was carried out using propidium iodide staining and flow cytometry analysis. Colchicine was found to be a potent G2/M cell cycle blocker (p≤0.001) compared to its untreated control. Finally the effect of the drugs on the migration of SCC040 cells was assessed using a wound-healing assay. Colchicine was found to significantly inhibit migration compared to its vehicle control (79.55 ± 4.02% reduction p≤0.001). These results suggest that zinc acetate and colchicine are potential candidates for less toxic therapies in HNC patients."],"dc:format":["application/pdf"],"dc:identifier.uri":["http://etheses.bham.ac.uk//id/eprint/5420/1/Shakir14MRes.pdf","http://etheses.bham.ac.uk//id/eprint/5420/2/Decl_IS_Shakir14MRes.pdf"],"dc:language.dcterms_iso639_2":["eng"],"dc:publisher.department":["College of Medical & Dental Sciences","Institute of Cancer Studies"],"dc:publisher.institution":["University of Birmingham"],"dc:relation.isreferencedby":["http://etheses.bham.ac.uk//id/eprint/5420/"],"dc:subject":["RC0254 Neoplasms. Tumors. Oncology (including Cancer)"],"dcterms:accessrights":["public","staffonly"],"dc:title":["An investigation into mechanisms of action of colchicine, zinc acetate and paracetemol - potential candidates for drug repurposing in head and neck cancer therapy"],"dc:type":["Thesis"],"dc:type.qualificationlevel":["m_rs"],"dc:type.qualificationname":["m_rs"]},"updated_at":"2026-11-19T09:28:23Z"}